ArticleBMB reports2026
Lefty2 prevents RANKL-induced bone loss by inhibiting osteoclast differentiation.
Article in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left-right determination factor 2 (Lefty2) is a transforming growth factor-β (TGF-β) receptor ligand that is critical for organ asymmetry and cell proliferation. More broadly, the TGF-β superfamily plays indispensable roles in development and gene regulation, and TGF-β family ligands are instrumental in osteoclast differentiation and bone resorption. In the present study, we show that Lefty2 dramatically inhibits receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclast differentiation. We found that this effect was associated with inhibition of early intracellular signaling pathways activated by RANKL, which are important for osteoclast differentiation. Furthermore, administration of exogenous Lefty2 prevented RANKLinduced bone loss in mice. Interestingly, transgenic mice expressing Lefty2 controlled by the Mx-1 promoter did not show a distinct bone phenotype, even though transgenic mouse-derived bone marrow macrophages exhibited reduced osteoclast formation compared to controls in vitro. [BMB Reports 2026; 59(1): 78-83].
Indexed as
Identifiers
40962326PMC12867179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.